Analysts Issue Forecasts for VERA Q1 Earnings

Vera Therapeutics, Inc. (NASDAQ:VERA) – Equities research analysts at HC Wainwright issued their Q1 2025 earnings estimates for shares of Vera Therapeutics in a report issued on Monday, May 5th. HC Wainwright analyst A. He expects that the company will post earnings per share of ($0.81) for the quarter. HC Wainwright currently has a “Buy” rating and a $75.00 target price on the stock. The consensus estimate for Vera Therapeutics’ current full-year earnings is ($2.89) per share. HC Wainwright also issued estimates for Vera Therapeutics’ Q3 2025 earnings at ($0.79) EPS and Q4 2025 earnings at ($0.77) EPS.

VERA has been the topic of several other research reports. Wedbush cut their price target on Vera Therapeutics from $34.00 to $26.00 and set a “neutral” rating on the stock in a research note on Wednesday. JPMorgan Chase & Co. cut their price target on Vera Therapeutics from $77.00 to $71.00 and set an “overweight” rating on the stock in a research note on Tuesday, March 4th. Wolfe Research began coverage on Vera Therapeutics in a research note on Tuesday, February 4th. They set an “outperform” rating and a $49.00 price objective for the company. Guggenheim increased their target price on Vera Therapeutics from $59.00 to $61.00 and gave the company a “buy” rating in a research note on Thursday, February 27th. Finally, The Goldman Sachs Group started coverage on Vera Therapeutics in a research report on Tuesday, January 28th. They set a “buy” rating and a $58.00 target price for the company. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat, Vera Therapeutics currently has a consensus rating of “Buy” and an average price target of $63.80.

Vera Therapeutics Trading Up 2.8 %

Shares of VERA opened at $22.62 on Wednesday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 13.76 and a current ratio of 13.76. The company has a market cap of $1.44 billion, a price-to-earnings ratio of -8.67 and a beta of 1.28. The stock has a fifty day moving average price of $24.48 and a two-hundred day moving average price of $34.98. Vera Therapeutics has a 52-week low of $18.53 and a 52-week high of $51.61.

Vera Therapeutics (NASDAQ:VERA) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.06). During the same period in the prior year, the business earned ($0.56) EPS.

Institutional Investors Weigh In On Vera Therapeutics

Several institutional investors have recently added to or reduced their stakes in VERA. Barclays PLC boosted its position in Vera Therapeutics by 94.1% during the 3rd quarter. Barclays PLC now owns 85,395 shares of the company’s stock worth $3,774,000 after acquiring an additional 41,394 shares during the last quarter. SG Americas Securities LLC grew its position in Vera Therapeutics by 116.7% in the fourth quarter. SG Americas Securities LLC now owns 20,270 shares of the company’s stock valued at $857,000 after purchasing an additional 10,916 shares in the last quarter. KBC Group NV increased its stake in Vera Therapeutics by 127.2% in the 4th quarter. KBC Group NV now owns 2,477 shares of the company’s stock valued at $105,000 after buying an additional 1,387 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its position in Vera Therapeutics by 27.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 13,427 shares of the company’s stock worth $568,000 after buying an additional 2,882 shares in the last quarter. Finally, Jennison Associates LLC lifted its position in Vera Therapeutics by 82.0% during the 4th quarter. Jennison Associates LLC now owns 813,861 shares of the company’s stock worth $34,418,000 after buying an additional 366,763 shares in the last quarter. 99.21% of the stock is owned by institutional investors.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.